Cyclosporine a attenuates 3-nitropropionic acid-induced huntington-like symptoms in rats: Possible nitric oxide mechanism

International Journal of Toxicology

Volumn 29, Issue 3, 2010, Pages 318-325

  Kumar, Puneet ^a   Kalonia, Harikesh ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; Cyclosporine A; Huntington disease; Mitochondria; Nitric oxide; Oxidative stress

Indexed keywords

3 NITROPROPIONIC ACID; ARGININE; CATALASE; CYCLOSPORIN A; HYDROGEN PEROXIDE; MALONALDEHYDE; MITOCHONDRIAL ENZYME; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN MITOCHONDRION; CHEMICAL PARAMETERS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; HUNTINGTON CHOREA; HUNTINGTON DISEASE LIKE SYNDROME; LIPID PEROXIDATION; MALE; MOTOR ACTIVITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; ROTAROD TEST; TREATMENT OUTCOME;

ANIMALS; BODY WEIGHT; BRAIN; CATALASE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUNTINGTON DISEASE; LIPID PEROXIDATION; MALE; MITOCHONDRIA; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRIC OXIDE; NITRITES; NITRO COMPOUNDS; OXIDATIVE STRESS; PROPIONIC ACIDS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

ANIMALIA; RATTUS;

EID: 77953816682     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581810365568     Document Type: Article

References (47)

1. Harper PS The epidemiology of Huntington's disease. Hum Genet. 1992 ; 89 (4). 365-376.
2. Beal MF Energetic in the pathogenesis of neurodegenerative disease. Trends Neurosci. 2000 ; 23: 298-304.
3. Gutekunst AC, Francine N., Hersch SM Recent advances in Huntington's disease. Curr Opin Neurol. 2000 ; 13 (4). 445-450.
4. Jakel JR, William FM Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 2000 ; 23 (6). 239-245.
5. Alexi T., Borlongan CV, Faull RL, et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Neurobiology. 2000 ; 60 (5). 409-413.
6. Brouillet E., Condé F., Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol. 1999 ; 59 (5). 427-468.
7. Borlongan CV, Koutouzis TK, Freeman TB, Cahill DW, Sanberg PR Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res. 1995 ; 697 (1-2). 254-267.
8. Kumar P., Kumar A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2009 ; 33 (1). 100-108.
9. Kumar P., Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neurosci Res. 2009 ; 63 (4). 302-314.
10. Kiss JP, Vizi ES Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci. 2001 ; 24 (4). 211-215.
11. Brenman JE, Bredt DS Nitric oxide signaling in the nervous system. Methods Enzymol. 1996 ; 269: 119-129.
12. Dawson VL, Dawson TM Nitric oxide in neurodegeneration. Prog Brain Res. 1998 ; 118: 215-229.
13. Pérez-Severiano F., Escalante B., Vergara P., Ríos C., Segovia J. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res. 2002 ; 951 (1). 36-42.
14. Deckel AW Nitric oxide and nitric oxide synthase in Huntington's disease. J Neurosci Res. 2001 ; 64 (2). 99-107.
15. Deshpande SB, Hida H., Takei-Io N., Masuda T., Baba H., Nishino H. Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res. 2006 ; 1108 (1). 205-215.
16. Galat A., Metcalfe SM Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol. 1995 ; 63 (1). 67-118.
17. Yamaguchil T., Kazuto M., Futoshi S., Atushi I., Hiroyuki U. Effect of cyclosporine on immediate early gene in rat globalm ischemia and its neuroprotection. J Pharmacol Sci. 2006 ; 100 (1). 73-81.
18. Leventhal L., Sortwell CE, Hanbury R., Collier TJ, Kordower JH, Palfi S. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J Comp Neurol. 2000 ; 425 (4). 471-478.
19. Kaminska B., Gaweda-Walerych K., Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants facts and hypotheses. J Cell Mol Med. 2004 ; 8 (1). 45-58.
20. Krystyna DJ, Leonora B., Joanna DU, Hanna KO, Anna S., Barbara ZO Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm. Mol Brain Res. 2004 ; 121 (1-2). 50-59.
21. Kumar P., Padi SS, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol. 2006 ; 17 (5-6). 485-492.
22. Wills ED Mechanism of lipid peroxide formation in animal. Biochem J. 1966 ; 99 (3). 667-676.
23. Green LC, Wagner DA, Glogowski J., Skipper PL, Wishnok JS, Tannebaum SR Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Ann Biochem. 1982 ; 126 (1). 131-138.
24. Luck H. Catalase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. New York: Academic Press; 1971: 885-893.
25. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophysics. 1978 ; 186: 189-195.
26. Gornall AG, Bardawill CJ, David MM Determination of serum proteins by means of the Biuret reaction. J Biol Chem. 1949 ; 177 (2). 751-766.
27. Berman SB, Hastings TG Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem. 1999 ; 73 (3). 1127-1137.
28. King TE, Howard RL Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol. 1967 ; 10: 275-284.
29. King TE Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol. 1967 ; 10: 322-331.
30. Sottocasa GL, Kuylenstierna B., Ernster L., Bergstrand A. An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol. 1967 ; 32 (2). 415-428.
31. Liu Y., Peterson DA, Kimura H., Schubert D. Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem. 1997 ; 69 (2). 581-593.
32. Borlongan CV, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Cyclosporine A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. Surg Neurol. 1996 ; 46 (4). 384-398.
33. Hernández-Espinosa D., Morton AJ Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. Brain Res Bull. 2006 ; 69 (6). 669-679.
34. Liu J., Farmer JD Jr, Lane WS, Friedman J., Weissman I., Schreiber SL Calcineurin is a common target of cyclophilin cyclosporin A and FKBP-FK506 complexes. Cell. 1991 ; 66 (4). 807-815.
35. Long Y., Xin CY, Jun KY, Ying HG, Fang FY, Qian F., Xiu LL. Cyclosporin A suppresses proliferation of endothelial progenitor cells: involvement of nitric oxide synthase inhibition. Inter Med. 2008 ; 47 (16). 1457-1464.
36. Montilla P., T°nez I., Muñoz MC, et al. Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur J Pharmacol. 2004 ; 488 (1-3). 19-25. (Pubitemid 38388519)
37. Tunez I., Montilla P., Del Carmen MM, Feijoo M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res. 2004 ; 37 (4). 252-256.
38. Kumar P., Padi SS, Naidu PS, Kumar A. Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find Exp Clin Pharmacol. 2007 ; 29 (1). 1-7.
39. Nishimura M., Okimura Y., Fujita H., et al. Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine. Cell Biochem Funct. 2008 ; 26 (8). 881-891.
40. Kristal BS, Stavrovskaya IG, Narayanan MV, et al. The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr. 2004 ; 36 (4). 309-312.
41. Ruan Q., Lesort M., MacDonald ME, Johnson GV Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet. 2004 ; 13 (7). 669-681.
42. Palacios-Callender M., Hollis V., Frakich N., Mateo J., Moncada S. Cytochrome c oxidase maintains mitochondrial respiration during partial inhibition by nitric oxide. J Cell Sci. 2007 ; 120 (pt 1). 160-165.
43. Friberg H., Ferrand-Drake M., Bengtsson F., Halestrap AP, Wieloch T. Cyclosporin-A, but not FK-506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci. 1998 ; 18 (14). 5151-5519.
44. Signoretti S., Marmarou A., Tavazzi B., et al. The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury. J Neurotrauma. 2004 ; 21 (9). 1154-1167.
45. Begley DJ, Squires LK, Zlokovi BV, et al. Permeability of the blood-brain barrier to the immunosuppressive cyclic peptide cyclosporin A. J Neurochem. 1990 ; 55 (4). 1222-1230.
46. Sakata A., Tamai I., Kawazu K., et al. In vivo evidence for ATPdependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier. Biochem Pharmacol. 1994 ; 48 (10). 1989-1992. (Pubitemid 24355031)
47. Bernareggi A., Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm. 1991 ; 19 (1). 21-50.